NCT00617591 - Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Multiple Myeloma

Interventions

DRUG

Lenalidomide

25 mg orally on days 1-21

DRUG

Pegylated Liposomal Doxorubicin (PLD)

40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)

DRUG

Dexamethasone

40 mg orally on days on 1-4

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa